Blog von Dr. med. Lothar M. Kirsch / 祁建德 // Rheumatic Diseases / Fibromyalgia / Travels / Languages / Poetry
Friday, July 20, 2012
Comments and Abstracts from the 2012 EULAR Meeting in Berlin
Comments and Abstracts from the 2012 EULAR Meeting in Berlin. Somehow this is an inventory of blogposts:
Biosimilars
Celltrion will most probably launch an infliximab biosimilar in 2013. http://rheumatologe.blogspot.de/2012/06/biosimilars.html
Ustekinumab
Ustekinumab and other options in psoriatic arthritis. http://rheumatologe.blogspot.de/2012/07/ustekinumab-and-other-options-in.html
Anti-CD-20 Monoclonal Antibody (like Rituximab)
Ofatumumab and ocrelizumab? have been analyzed in:
[AB0572] META-ANALYSIS OF THE KEY RHEUMATOID ARTHRITIS (RA) DISEASE ACTIVITY ENDPOINTS IN PATIENTS TREATED WITH B-CELL DEPLETING THERAPIES
S. Menon, K. Barker, E. Peeva, I. Gourley, A. Heatherington. Research and Development, Pfizer Inc, Cambridge, United States
http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html
Co-Stimulation-Inhibition
Subcutaneous abatacept, when will it be available?
I have an idea about this, but up to now couldn’t confirm the date.
Tocilizumab
In a head to head study tocilizumab monotherapy has been studied against humira monotherapy. http://rheumatologe.blogspot.de/2012/06/tocilizumab-monotherapy-vs-humira.html
Concerning Tocilizumab, my most important question to solve at the EULAR 2012 has been: How about subcutaneous tocilizumab? http://rheumatologe.blogspot.de/2012/06/tocilizumab-at-eular-2012.html
Sarilumab
Sarilumab, another anti-IL-6 monoclonal antibody, has already been in a phase 2 study last year, what’s new? http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html
Sirukumab
Sirukumab (formerly known as CNTO 136) is a human MAB that binds to the cytokine IL-6
http://rheumatologe.blogspot.de/2012/07/sirukumab-at-eular-2012.htmlAtacicept
Has atacicept [works on BLys(B-lymphocyte stimulator) and APRIL (A PRoliferation Inducing Ligand)] shown new efficacy? http://rheumatologe.blogspot.de/2012/06/atacicept.html
Pateclizumab
Pateclizumab is an anti-Lymphotoxin-alpha Monoclonal Antibody. http://rheumatologe.blogspot.de/2012/06/pateclizumab-anti-lymphotoxin-alpha.html
Secukinumab
Secukinumab (an Anti-Il17a Monoclonal Antibody). http://rheumatologe.blogspot.de/2012/06/secukinumab-anti-il17a-monoclonal.html
Small molecules / protein kinase inhibitors
Safety of different small molecules / protein kinase inhibitors
http://rheumatologe.blogspot.de/2012/06/safety-of-different-small-molecules.html
Tofacitinib
The oral jak inhibitor tofacitinib (CP-690,550) has attracted most attention. http://rheumatologe.blogspot.de/2012/07/tofacitinib-oral-jak-inhibitor-at-eular.html
Fostamatinib
Concerning fostamatinib (a SYK inhibitor), how far have we come during the past year? http://rheumatologe.blogspot.de/2012/07/fostamatinib-at-eular-2012.html
VX-509
VX-509, a JAK 3 directed small molecule
http://rheumatologe.blogspot.de/2012/07/vx-509-and-eular-2012.htmlAnakinra - IL-1Ra-Receptor antagonist
Anakinra and Pseudogout (calcium pyrophosphate crystal arthritis) at the EULAR 2012
http://rheumatologe.blogspot.de/2012/07/anakinra-and-pseudogout-calcium.html
SBI-087
SBI-087 is a SMIP (= small molecule immune pharmaceutical) binding to CD-20 http://rheumatologe.blogspot.de/2012/07/sbi-087-at-eular-2012.html
Mavrilimumab
Mavrilimumab is a human MAB for the treatment of rheumatoid arthritis. It targets the GMCSF receptor and alpha-chain. http://rheumatologe.blogspot.de/2012/07/mavrilimumab-at-eular-2012.html
NKG2a
NNC141-0100 is a humanized anti-human NKG2A monoclonal antibody that blocks interaction between CD94/NKG2A.
http://rheumatologe.blogspot.com/2012/07/nkg2a-nnc141-0100-at-eular-2012.html
Cetrorelix
Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist). http://rheumatologe.blogspot.de/2012/07/cetrorelix-at-eular-2012.html
CCX354-C
CCX354-C did better than expected. http://rheumatologe.blogspot.de/2012/07/ccx-354-c-at-eular-2012.html
Dekavil
Dekavil - fibronectin-A-chain connected to IL-10
http://rheumatologe.blogspot.de/2012/07/dekavil-at-eular-2012.html
Baricitinib
Baricitinib (also known as INCB28050, LY3009104) is an oral JAK1 and JAK2 inhibitor.
http://rheumatologe.blogspot.de/2012/06/baricitinib-ly3009104-at-eular-2012-in.html
Iguratimod
Iguratimod is new DMARD is under way from Japan:
http://rheumatologe.blogspot.de/2012/06/iguratimod-at-eular-2012.html
Modified release prednisolone
On modified release prednisolone: http://rheumatologe.blogspot.de/2012/06/modified-release-prednisone.html
Synavive
Synavive, a combination of 2 mgs of prednisolone and 200 mgs of dipyramidole
http://rheumatologe.blogspot.de/2012/07/synavive-crx-102-at-eular-2012.html
Acronyms of studies in rheumatology:
http://rheumatologe.blogspot.de/2012/06/acronyms-of-studies-in-rheumatoid.html
Tabalumab
Tabalumab is an anti-BAFF Monoclonal Antibody. http://rheumatologe.blogspot.de/2012/06/tabalumab-ly2127399-anti-baff.html
Rheumatoid Arthritis
Persistant Synovitis of Rheumatoid Arthritis in Remission http://rheumatologe.blogspot.de/2012/07/persistant-synovitis-of-rheumatoid.htmlAnkylosing Spondylitis
Ankylosing Spondylitis Refractory to TNF-inhibition in the light of EULAR 2012. http://rheumatologe.blogspot.de/2012/07/ankylosing-spondylitis-refractory-to.html
Psoriatic Arthritis
Non-anti-TNF Biologics in Psoriatic Arthritis at EULAR 2011. http://rheumatologe.blogspot.de/2012/07/non-anti-tnf-biologics-in-psoriatic.html
Gout and other crystal diseases
Gout and other crystal diseases / Canakinumab.
http://rheumatologe.blogspot.de/2012/07/gout-and-other-crystal-diseases-at.html
Fibromyalgia
Fibromyalgia and the influence of weather on symptoms. http://rheumatologe.blogspot.de/2012/06/fibromyalgia-and-influence-of-weather.html
Chronic Widespread Pain – a study presented at the EULAR 2012. http://rheumatologe.blogspot.de/2012/07/chronic-widespread-pain-study-presented.html
Osteoarthritis
Strontium ranelate in Knee Osteoarthritis at the EULAR 2012
http://rheumatologe.blogspot.de/2012/07/strontium-ranelate-in-knee.html
CD-40
This is a very speculative subject, but who knows, maybe we're going to target CD-40 to treat rheumatoid arhtiris:
http://rheumatologe.blogspot.de/2012/08/targeting-cd-40-preliminaries-at-eular.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment